Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 5
2020 10
2021 11
2022 5
2023 5
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
Morganti S, Jin Q, Vincuilla J, Buehler R, Ryan S, Stokes S, Parker T, Mittendorf EA, King TA, Weiss A, Partridge AH, Bychkovsky BL, Curigliano G, Tayob N, Lin NU, Garber JE, Tolaney SM, Lynce F. Morganti S, et al. NPJ Breast Cancer. 2024 Apr 16;10(1):28. doi: 10.1038/s41523-024-00632-8. NPJ Breast Cancer. 2024. PMID: 38627457 Free PMC article.
PARP Inhibitors for Breast Cancer Treatment: A Review.
Morganti S, Marra A, De Angelis C, Toss A, Licata L, Giugliano F, Taurelli Salimbeni B, Berton Giachetti PPM, Esposito A, Giordano A, Bianchini G, Garber JE, Curigliano G, Lynce F, Criscitiello C. Morganti S, et al. JAMA Oncol. 2024 Mar 21. doi: 10.1001/jamaoncol.2023.7322. Online ahead of print. JAMA Oncol. 2024. PMID: 38512229
Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer.
Tarantino P, Ajari O, Graham N, Vincuilla J, Parker T, Hughes ME, Tayob N, Garrido-Castro AC, Morganti S, King TA, Mittendorf EA, Curigliano G, Lin NU, Tolaney SM. Tarantino P, et al. Among authors: morganti s. Eur J Cancer. 2024 Apr;201:113920. doi: 10.1016/j.ejca.2024.113920. Epub 2024 Feb 10. Eur J Cancer. 2024. PMID: 38368741 Review.
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer.
Morganti S, Gibson CJ, Jin Q, Santos K, Patel A, Wilson A, Merrill M, Vincuilla J, Stokes S, Lipsyc-Sharf M, Parker T, King TA, Mittendorf EA, Curigliano G, Hughes ME, Stover DG, Tolaney SM, Weeks LD, Tayob N, Lin NU, Garber JE, Miller PG, Parsons HA. Morganti S, et al. J Clin Oncol. 2024 Jan 8:JCO2301071. doi: 10.1200/JCO.23.01071. Online ahead of print. J Clin Oncol. 2024. PMID: 38190580
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study.
Morganti S, Marra A, Gandini S, Ascione L, Ivanova M, Venetis K, Sajjadi E, Zagami P, Giugliano F, Taurelli Salimbeni B, Berton Giachetti PPM, Corti C, De Camilli E, Curigliano G, Fusco N, Criscitiello C. Morganti S, et al. Eur J Cancer. 2023 Dec;195:113397. doi: 10.1016/j.ejca.2023.113397. Epub 2023 Oct 23. Eur J Cancer. 2023. PMID: 37890353
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.
Nicolò E, Tarantino P, D'Ecclesiis O, Antonarelli G, Boscolo Bielo L, Marra A, Gandini S, Crimini E, Giugliano F, Zagami P, Corti C, Trapani D, Morganti S, Criscitiello C, Locatelli M, Belli C, Esposito A, Minchella I, Cristofanilli M, Tolaney SM, Curigliano G. Nicolò E, et al. Among authors: morganti s. Oncologist. 2024 Jan 5;29(1):75-83. doi: 10.1093/oncolo/oyad212. Oncologist. 2024. PMID: 37548439 Free PMC article. Review.
Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls.
Morganti S, Ivanova M, Ferraro E, Ascione L, Vivanet G, Bonizzi G, Curigliano G, Fusco N, Criscitiello C. Morganti S, et al. Cancer Drug Resist. 2022 Oct 20;5(4):971-980. doi: 10.20517/cdr.2022.55. eCollection 2022. Cancer Drug Resist. 2022. PMID: 36627895 Free PMC article.
40 results